Nephroprotective effects with SGLT2i in CKD patients - PACE-CME

Nephroprotective effects with SGLTi in CKD patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Strong evidence for colchicine in patients with chronic coronary disease
Strong evidence for colchicine in patients with chronic coronary disease
ESC 2020
Strong evidence for colchicine in patients with chronic coronary disease
- Aernoud Fiolet, MD
- Aernoud Fiolet, MD, PhD
Incredible consistency between two SGLT2i trials in HFrEF
Incredible consistency between two SGLT2i trials in HFrEF
ESC 2020
Incredible consistency between two SGLT2i trials in HFrEF
- Milton Packer, MD
Updates in the 2020 AF guidelines
Updates in the 2020 AF guidelines
ESC 2020
Updates in the 2020 AF guidelines
- Isabelle van Gelder, MD, PhD
Colchicine reduces primary outcome in chronic coronary disease
Colchicine reduces primary outcome in chronic coronary disease
ESC 2020
Colchicine reduces primary outcome in chronic coronary disease
- Mark Nidorf, MD